Anti-PD-L1/MUC1 CAR-pNK cell therapy (PersonGen Biomedicine/Anke Biotechnology)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-PD-L1/MUC1 CAR-pNK cell therapy (PersonGen Biomedicine/Anke Biotechnology)
Drug Alias NameCAR-pNK (PersonGen Biomedicine/Anke Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionAnti-MUC1
TargetsMucin-1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesAnhui Anke Biotechnology (Group) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co LtdAnhui Anke Biotechnology (Group) Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A